Loading data
EMRNYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 18.02 bn USD | 17.49 bn USD | 15.17 bn USD | 1.66 bn USD | 13.8 bn USD |
| Cost of revenue | 8.5 bn USD | 8.61 bn USD | 7.74 bn USD | — | 7.5 bn USD |
| Gross profit | 9.52 bn USD | 8.89 bn USD | 7.43 bn USD | — | 6.31 bn USD |
| Research and development expense | 771 m USD | 781 m USD | 523 m USD | — | 385 m USD |
| Selling, general and administrative expense | 5.1 bn USD | 5.14 bn USD | 4.19 bn USD | — | 3.61 bn USD |
| Profit before tax | 2.93 bn USD | 2.02 bn USD | 2.9 bn USD | — | 2.43 bn USD |
| Income tax expense | 696 m USD | 415 m USD | 642 m USD | — | 549 m USD |
| Net income (reported basis) | 2.29 bn USD | 1.97 bn USD | 13.22 bn USD | — | 3.23 bn USD |
| Basic earnings per share | 4.06 USD/share | 3.44 USD/share | 23 USD/share | — | 5.44 USD/share |
| Diluted earnings per share | 4.04 USD/share | 3.43 USD/share | 22.88 USD/share | — | 5.41 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.